Diabetic Retinopathy Diagnostic Assay Development Service
Diabetic retinopathy (DR) is one of the leading causes of blindness, and the development of diagnostic methods is critical for enabling early intervention and disease management. Ace Therapeutics possesses extensive experience in animal modeling and interdisciplinary research in diabetes and its complications. We are committed to leveraging our expertise and technology platform to provide integrated solutions from biomarker screening to translation of diagnostic tools for pharmaceutical companies, medical device companies and research institutions worldwide.
Current Status of The Diagnosis of Diabetic Retinopathy
The prevalence of diabetes and its complications continue to rise. However, traditional screening methods have bottlenecks such as low sensitivity, poor accessibility and high cost. New technologies focus on early disease detection. Technological innovations such as remote ophthalmology, smartphone-based photography, deep learning artificial intelligence or wide-angle photography can improve diagnostic accuracy and speed up treatment. The emergence of these new technologies offers new hope for accurate diagnosis of diabetic retinopathy.
Our Diabetic Retinopathy Diagnostic Assay Development Services
Ace Therapeutics provides comprehensive diagnostic development support, spanning from disease mechanism research to preclinical translational validation.
Animal Modeling and Phenotype Evaluation
| Classical induction models |
Streptozotocin (STZ)-induced diabetic rats/mice, high-fat diet combined with low-dose STZ modeling. |
| Genetically engineered models |
db/db mice, VEGF overexpression/knockout models, AGEs receptor (RAGE) defective models. |
| Customized models of complications |
Early microangiopathy (basement membrane thickening), mid-stage exudative lesion (retinal edema), late proliferative lesion (neovascularization) model. |
Gold Standard for Phenotypic Testing
- Fundus imaging techniques: non-dilated fundus photography (simulates clinical screening), fluorescein fundus angiography (FFA) to detect vascular leakage.
- Histopathologic analysis: PAS staining to quantify basement membrane thickness, CD31 immunohistochemistry to assess vessel density.
- Functional assessment: Electroretinography (ERG) to detect retinal cell damage and construct a structure-function correlation database.
Biomarker Screening and Assay Development
Multidimensional marker discovery
- Humoral markers: quantification of inflammatory factors such as serum/atrial fluid VEGF, IL-6, TNF-α, etc. using ELISA / mass spectrometry platform.
- Cellular molecular markers: retinal Müller cell GFAP expression was measured using immunofluorescence, and pericyte apoptosis was detected using TUNEL staining.
- Novel target discovery: single-cell sequencing technology to explore DR-specific cell subpopulation markers (e.g. endothelial cell death-related gene GSDMD).
Assay Optimization
- Developed a high sensitivity ELISA kit (detection limit of 0.1 pg/mL), suitable for the detection of mouse micro samples.
- Establishment of multiple immunohistochemistry (mIHC) technology platform for co-localization of multiple markers in retinal tissues.
Diagnostic reagent development support:
- Antibody/Adaptor Affinity Validation (SPR technology): assesses marker capture efficiency and specificity.
- Simulated Clinical Sample Matrix: Contains a library of sera from different stages of diabetes and combined cataract/glaucoma interference samples.
Preclinical testing of imaging devices:
- Portable fundus camera performance validation: contrast resolution and vessel recognition in STZ rat model in agreement with clinical equipment.
- Optimization of OCT (Optical Coherence Tomography) parameters: modeling quantitative analysis of thickness changes in retinal layers.
Why Choose Our Diabetic Retinopathy Diagnostic Assay Development Services?
- Advanced technology platform: Multi-omics analysis platform combined with standardized quality control ensures reliable data for clients.
- Flexible Collaboration Solutions: From single technology service (e.g. model building / marker testing) to full process development (from target discovery to IVD tool validation).
- Rapid Response Mechanism: Provide initial program design within 72 hours, with dedicated project managers to follow up on core projects.
Whether exploring novel biomarkers or optimizing existing diagnostic tools, Ace Therapeutics' expert team delivers customized solutions to propel your projects forward. Contact us to unlock the potential of our services. We're dedicated to supporting your research goals.
Reference
- Kąpa, Maria, et al. Modern Approach to Diabetic Retinopathy Diagnostics. Diagnostics. 14.17 (2024): 1846.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
